Pharmacogenetics of anti-HIV drugs.
Pharmacogenetics holds promise in HIV treatment because of the complexity and potential toxicity of multidrug therapies that are prescribed for long periods. Thus far, few candidate genes have been examined for a limited number of allelic variants, but a number of confirmed associations have already emerged. A change in paradigm emerges from the availability of the HapMap, the wealth of data on less-common genetic polymorphisms, and new genotyping technology. This review presents a comprehensive analysis of the existing literature on pharmacogenetic determinants of antiretroviral drug exposure, drug toxicity, as well as genetic markers associated with the rate of disease progression. It is expected that larger-scale comprehensive genome approaches will profoundly change the landscape of knowledge in the future.
Telenti
A
A
Institute of Microbiology, University of Lausanne, Lausanne, Switzerland. amalio.telenti@chuv.ch
Zanger
U M
UM
D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D018450:Disease Progression; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D019380:Anti-HIV Agents; D005819:Genetic Markers